DIM-LF11-318

General Information


DRACP ID  DRACP00561

Peptide Name   DIM-LF11-318

Sequence  FWQRRIRRWRRFWQRRIRRWRR

Sequence Length  22

UniProt ID  Not available

PubChem CID  Not available

Origin  Human lactoferricin derived

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A-375 Amelanotic melanoma Carcinoma LC50=9.3±0.8 µM MTS assay 24h 1
SBcl-2 Serum B cell lymphoma 2 Lymphoma LC50=9.4±0.5 µM MTS assay 24h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Normal Human Dermal Fibroblasts (NHDF): LC50=13.9±0.4 µM

Target  Not available

Affinity  Not available

Mechanism  Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00561

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C156H242N64O25

Absent amino acids  ACDEGHKLMNPSTVY

Common amino acids  R

Mass  378876

Pl  13.54

Basic residues  12

Acidic residues  0

Hydrophobic residues  8

Net charge  12

Boman Index  -16500

Hydrophobicity  -227.27

Aliphatic Index  35.45

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  22000

Absorbance 280nm  1047.62

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 26239537

Title  Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine

Doi 10.1016/j.bbamem.2015.07.018

Year  2015

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.